Argent BioPharma Ltd (ASX: RGT) (OTCQB: RGTLF), an Australia-based clinical-stage biopharmaceutical company, announced on Sunday positive Phase IIb clinical trial results for CimetrA, an anti-inflammatory treatment.

The company says that the study confirmed the product's strong safety profile and demonstrated faster recovery times in COVID-19 patients. It revealed no drug-related adverse events, reinforcing CimetrA's safety; faster clinical improvement compared to placebo, measured by the WHO Ordinal Scale; reduced inflammation, with modulation of key inflammatory markers (IL-6, IL-1 beta, TNF-alpha, and more); and improved quality of life trends in treated patients

With these findings, Argent BioPharma continues to advance innovative therapies. One such therapy, CannEpil, is an oral mucosal solution with a high-CBD, low-THC formulation.

CEO Roby Zomer said: "These promising results highlight CimetrA®'s potential as a breakthrough treatment for inflammatory diseases beyond COVID-19. We are excited about its future clinical development."